Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

4.160 -0.030 (-0.72%)

Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm

March 21, 2026

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

March 10, 2026

From Pomerantz LLP

Via GlobeNewswire

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

February 09, 2026

From Nuvation Bio

Via Business Wire

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Nuvation Bio

Via Business Wire

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

January 12, 2026

From Nuvation Bio and Eisai

Via Business Wire

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

December 03, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

November 26, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

October 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 07, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 05, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

June 24, 2025

From Nuvation Bio

Via Business Wire

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

June 11, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 13, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

May 12, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Present at The Citizens Life Sciences Conference

May 01, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

April 22, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

April 02, 2025

From Nuvation Bio Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.